Clinical Trials
20 trialsNCT01127295 2026-04-14
PHACS
Institut Claudius Regaud
Phase 4 Completed
NCT01553903 2026-04-14
OXYTAM
Institut Claudius Regaud
Phase 4 Completed
NCT01612871 2026-04-14
MIRHO
Institut Claudius Regaud
Phase 4 Completed
NCT05161195 2026-04-02
Roll-over Study to Allow Continued Access to Ribociclib
Novartis
Phase 4 Active not recruiting
NCT02661932 2025-01-31
Brovale
Erasme University Hospital
Phase 4 Completed
NCT03355157 2024-10-01
PADMA
GBG Forschungs GmbH
Phase 4 Completed
NCT01035099 2022-12-13
RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF
Weill Medical College of Cornell University
Phase 4 Completed
NCT03948568 2022-09-30
REaCT-RETT
Ottawa Hospital Research Institute
Phase 4 Completed
NCT02679755 2022-07-27
Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer
Pfizer
Phase 4 Completed
NCT03220178 2022-01-06
PRECYCLE
Palleos Healthcare GmbH
Phase 4 Terminated
NCT04137640 2021-07-20
Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy
Shengjing Hospital
Phase 4 Not yet recruiting
NCT00688909 2021-06-09
REAL
Novartis
Phase 4 Completed
NCT03238703 2018-12-27
Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
Fred Hutchinson Cancer Center
Phase 4 Withdrawn
NCT00375752 2017-06-26
FEMZONE
Novartis
Phase 4 Terminated
NCT00237133 2017-02-24
PREDICT
Novartis
Phase 4 Completed
NCT00014638 2013-02-21
Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
Novartis
Phase 4 Completed
NCT00241046 2012-04-19
Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment
Novartis
Phase 4 Terminated
NCT00171847 2010-03-31
eLEcTRA
Novartis
Phase 4 Terminated
NCT01072318 2010-02-22
LEXTOP
Korean Breast Cancer Study Group
Phase 4 Unknown
NCT00237224 2009-11-19
Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole
Novartis
Phase 4 Completed